Elsevier

Life Sciences

Volume 36, Issue 3, 21 January 1985, Pages 207-212
Life Sciences

Current concepts
II. Selective accumulation of MPP+ in the substantia nigra: A key to neurotoxicity?

https://doi.org/10.1016/0024-3205(85)90060-8Get rights and content

Abstract

The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is rapidly metabolized to a 1-methyl-4-phenylpyridinium species (MPP+) in the squirrel monkey. After administration of toxic doses of MPTP, the concentration of MPP+ in the substantia nigra appears to increase during the first 72 hours, reaching the highest concentration of any central nervous system (CNS) tissue studied. In contrast, the concentration of this compound in other brain areas suggested time dependent elimination during the same period. Pretreatment of animals with the monoamine oxidase (MAO) inhibitor pargyline blocks both the neurotoxic action and the biotransformation of MPTP. In animals given pargyline and MPTP, initial MPTP levels are much higher in all brain regions than in those not receiving pargyline, but by 12 hours, MPTP levels had fallen rapidly in all regions except the substantia nigra and the eye. It may be that the selective toxicity of MPTP is related in some way to the accumulation of its oxidized metabolite in the substantia nigra.

References (13)

  • G.C. Davis et al.

    Psychiatry Res.

    (1979)
  • J.W. Langston et al.

    Neurosci. Lett.

    (1984)
  • K. Chiba et al.

    Biochem. Biophys. Res. Commun.

    (1984)
  • R.E. Lyle et al.

    Tetrahedron Lett.

    (1962)
  • A. Ziering et al.

    J. Org. Chem.

    (1947)
  • J.W. Langston et al.

    Science

    (1983)
There are more references available in the full text version of this article.

Cited by (158)

  • Opportunities and challenges related to saturation of toxicokinetic processes: Implications for risk assessment

    2021, Regulatory Toxicology and Pharmacology
    Citation Excerpt :

    In situations where there is a lack of a quantifiable relationship between free plasma concentration and adverse effect at the target site, it is more appropriate to use other dose metrics, such as tissue or even cell concentrations of the toxicologically critical penultimate moiety(moieties). For example, 1-methyl-4-phenylpyridinium (MPP+), the toxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), selectively targets dopaminergic cells of the substantia nigra where the compound has been shown to accumulate in primates, despite being eliminated in other parts of the brain (Irwin and Langston, 1985). This selective concentration of the toxic moiety illustrates the importance and feasibility of selecting a dose metric that is most relevant for the observed toxicity; in this example, the toxic moiety is metabolite substantia nigra concentration rather than blood AUC of the parent.

  • Basic Principles of Drug Discovery and Development

    2021, Basic Principles of Drug Discovery and Development
  • A new human pyridinium metabolite of furosemide, inhibitor of mitochondrial complex I, is a candidate inducer of neurodegeneration

    2019, Biochemical Pharmacology
    Citation Excerpt :

    Is this inhibition specific and persistent? The comparison with MPTP/MPP+ biodistribution studies in mice and monkeys [37,38], or with haloperidol and its pyridinium metabolites in human [25] reinforce the possibility for PoF resulting from furosemide metabolism, to cross the blood-brain-barrier and reach specific areas in the brain. Indeed, results from our in vivo investigations showed that five weeks after the end of exposure, PoF inhibited complex I activity of mice striatal mitochondria by 50%, and by 37% the one of cortical counterparts, resulting in a 25% and 15% decrease of the respiratory chain activity, respectively, thus indicating a greater sensibility of striatal versus cortical mitochondria complex I towards PoF (Fig. 3) [39].

  • Renal Organic Cation and Anion Transport: From Physiology to Genes

    2010, Comprehensive Toxicology, Second Edition
  • Non-human Primate Models of Parkinson's Disease and Experimental Therapeutics

    2008, Parkinson's Disease: Molecular and Therapeutic Insights From Model Systems
View all citing articles on Scopus
View full text